Company Interview / Archer's roadmap to medtch prototype

Archer Materials CEO (ASX: AXE) Simon Ruffell is excited about the company's roadmap of products. When it comes to Archer's medtech application, Ruffell says the next stage for the for 2026 is to turn that into a real prototype. That's will allow the product to get into clinical trials and the medical regulatory process to be approved to get it to market.

On Semiconductor Australia 2025: "It's about educating investors as well. I think Archer being the only ASX listed quatum company is a problem in some ways, because we're maybe the only one educating Australian investors right now. So it's an education thing. It's getting in front of potential investors and our shareholders."

*Partner content